Table 2

Comparison of tumor characteristics in different regions is shown in pre-drug treated tumor@ and post-treated tumor# by sodium MRI image intensity and histology, histo-immunology parameters as shown in Figures 5 and 6. By using eyepiece-micrometer square counter (100 squares per high power field), necrosis*(<25% cells in micrometer square), viable cells**(<60% cells in micrometer square) and apoptosis*** (20–40 apoptotic nuclei in HPF) and cyst space****(<100 μm) per HPF were premalignant histology characteristics. IC/EC space (% space in HPF), necrosis, viable cells are shown as number of micrometer squares with <25% necrosis area in HPF by histology. Apoptotic index (A.I.) and proliferation index (P.I.) are shown as average number of apoptotic nuclei per HPF and number of mitotic figures per HPF. S-DNA histogram area was measured by CAS 200 system in arbitrary units. Single strand-DNA mAb area was measured in digital images by Optimas 6.5 and ss-DNA mAb density was measured in arbitrary units of photomultiplier scanner.
Pre-drug treated@ Post-drug treated#
 Sodium MRI signal intensityd
 Histology (in HPF)
 A.I. (KI-67)
 P.I. (in HPF)
 S-DNA (histogram)
 ss-DNA mAb (density units)






Tumor feature
 IR
 SQ
 (CAS)
Control (n = 41)
 4.25 ± 1.0
 5.27 ± 2.0
 -
 -
 -
 -
 -








Sham (n = 40)
 4.30 ± 0.2
 5.38 ± 1.0












Tumor area(mm2;n = 16)@
 4.56 ± 0.30
 4.67 ± 0.30
 4.49 ± 0.2
 -
 -
 3.6 ± 0.2
 4.2 ± 0.2
Tumor area(mm2;n = 3)#
 4.60 ± 0.29
 4.61 ± 0.26
 4.42 ± 0.3
 -
 -
 3.5 ± 0.3
 4.3 ± 0.3








IC/EC space@
 60–70
65–76
 -
 -
 -
 -
IC/EC space#
 80–95
60–70
 -
 -
 -
 -








Necrosis*(squares)@
 gray
56 ± 32
 -
 270
 M-DNA
 -
Necrosis*(squares)#
 bright
50 ± 23
 -
 120
 M-DNA
 -








Viable**(squares)@
 dark
65 ± 21
 -
 -
 -
 -
Viable**(squares)#
 dark
76 ± 11
 -
 -
 -
 -








Apoptosis***(nuclei)@
 bright
40 ± 12
 150
 -
 S-DNA
 159 ± 12
Apoptosis***(nuclei)#
 bright
50 ± 13
 160
 -
 M or S-DNA
 129 ± 20








Cyst****(size in μm)@
 gray
120 ± 29
 -
 -
 -
 -
Cyst****(size in μm)#
 gray
80 ± 22
 -
 -
 -
 -

Sharma et al. Cancer Cell International 2005 5:26   doi:10.1186/1475-2867-5-26